A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Phase 1 – testing safety in a small group of people
Conditions:
Healthy Volunteers
Sponsor: Alnylam Pharmaceuticals
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Who can participate
Inclusion Criteria:
* Is willing and able to complete all study assessments
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has no history of invasive infection by an encapsulated organism
* Has no known complement or immunologic deficiency
БГ